Toujeo Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to rising prevalence of type 1 and type 2 diabetes, increased clinical acceptance of insulin glargine, expansion of diabetes treatment guidelines, improved insulin manufacturing scalability, wider availability of insulin therapies.

The growth in the forecast period can be attributed to increasing diabetes incidence globally, growing demand for convenient insulin administration, rising focus on long-term glycemic control, expansion of access to specialty diabetes care, increasing adoption of advanced insulin delivery formats. Major trends in the forecast period include increasing adoption of long-acting basal insulin therapies, growing preference for once-daily insulin regimens, rising use of prefilled insulin delivery devices, expansion of patient-centric diabetes management approaches, enhanced focus on glycemic stability.

The increasing prevalence of diabetes is expected to support the growth of the Toujeo market in the coming years. Diabetes is a chronic condition in which the body is unable to properly regulate blood sugar (glucose) levels due to insufficient insulin production or the inability to use insulin effectively. The rising prevalence of diabetes is driven by factors such as unhealthy diets and sedentary lifestyles, which significantly contribute to the global increase in cases. Toujeo helps manage blood sugar levels in individuals with type 1 and type 2 diabetes by providing a steady release of insulin over 24 hours, typically through a once-daily injection. For example, in 2025, according to the International Diabetes Federation, a Belgium-based health organization, approximately 589 million adults aged 20-79 were living with diabetes in 2024, with this number projected to reach 853 million by 2050, and over 80% of adults with diabetes residing in low- and middle-income countries. Therefore, the rising prevalence of diabetes is driving the growth of the Toujeo market.

The growth in healthcare investments is expected to contribute to the expansion of the Toujeo market going forward. Healthcare investments involve allocating capital to the healthcare sector, including funding for medical technologies, pharmaceuticals, healthcare facilities, and services. The increase in healthcare investments is driven by an aging population that raises demand for healthcare services, along with advancements in medical technology that foster innovation and improve patient care. These investments support Toujeo by funding clinical trials, expanding production, securing regulatory approvals, and enhancing distribution to ensure wider accessibility and adoption of the treatment. For instance, in December 2024, according to *Health Affairs*, a US-based health policy journal, healthcare spending in the United States reached $4.9 trillion in 2023, representing a 7.5% increase from a 4.6% growth rate in 2022. Therefore, rising healthcare investments are supporting the growth of the Toujeo market.

The increasing demand for personalized medicine is anticipated to drive the expansion of the Toujeo market in the future. Personalized medicine refers to medical approaches that tailor the prevention, diagnosis, and treatment of diseases to an individual’s unique genetic, environmental, and lifestyle factors. Growing demand for personalized medicine is fueled by the rising prevalence of chronic and genetic diseases, which require individualized treatments to improve patient outcomes and minimize adverse effects. Personalized medicine enhances Toujeo therapy by enabling insulin regimens tailored to each patient’s genetic profile, lifestyle, and glycemic patterns, improving efficacy while reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a US-based nonprofit organization, reported that the FDA approved 16 new personalized treatments for patients with rare diseases in 2023, up from six approvals in 2022, including seven cancer therapies and three treatments for other conditions. Therefore, the rising demand for personalized medicine is driving the growth of the Toujeo market.

Major companies operating in the toujeo market are Sanofi SA.

North America was the largest region in the toujeo market in 2025. The regions covered in the toujeo market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the toujeo market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs are impacting the toujeo market by increasing costs of imported active pharmaceutical ingredients, biologic excipients, specialized cartridges, and pen-delivery components used in long-acting insulin production. Pharmaceutical manufacturing hubs in Europe and North America are most affected due to cross-border sourcing of insulin raw materials, while Asia-Pacific faces pricing pressure on finished insulin exports. These tariffs are contributing to higher production and distribution costs, affecting pricing negotiations with healthcare providers. However, they are also encouraging localized insulin manufacturing, regional API sourcing, and investments in domestic biologics production infrastructure.

The toujeo market research report is one of a series of new reports that provides toujeo market statistics, including toujeo industry global market size, regional shares, competitors with a toujeo market share, detailed toujeo market segments, market trends and opportunities, and any further data you may need to thrive in the toujeo industry. This toujeo market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Toujeo is a long-acting insulin containing insulin glargine, used to help manage blood sugar levels in individuals with diabetes. Insulin glargine is a synthetic form of insulin that provides a steady release over an extended period, typically up to 24 hours, helping to regulate blood glucose effectively.

The primary indications for Toujeo include type 1 diabetes, type 2 diabetes, and pediatric diabetes. Type 1 diabetes is an autoimmune disorder in which the body’s immune system attacks insulin-producing cells in the pancreas, resulting in little or no insulin production. Toujeo is available in prefilled pens and vials and is distributed through hospital pharmacies, retail pharmacies, online pharmacies, and specialty pharmacies. It serves various end users, including adult, geriatric, and pediatric patients.

The toujeo market consists of sales of prefilled insulin pens, insulin detemir, insulin aspart, and insulin glargine. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.